Beyond the Manhattan Plot: Advanced Statistical Rigor and Multi-Omic Integration in Genome-Wide Analysis

Genome-wide analysis is easy to oversimplify. Many articles still frame it as a search for significant loci across the genome, followed by a Manhattan plot and a short list of top SNPs. That description is familiar, but it misses the hardest part of the work. The real challenge is not generating a peak. The real challenge is deciding whether that peak survives statistical scrutiny, whether it reflects phenotype biology rather than cohort structure, and whether it can be translated into a credible mechanistic hypothesis.

That distinction matters even more in large 2026-era datasets. Cohorts are bigger. Variant counts are higher. Population structure is more complex. Downstream expectations are also higher. A list of significant markers is no longer enough for most serious research programs. Teams want to know whether the analysis controlled false discovery well, whether hidden relatedness distorted the signal, whether the lead SNP is actually causal, and whether the locus can be connected to expression, splicing, or regulatory function in a defensible way.

This resource discusses genome-wide analysis methods in research-use workflows and is intended for experimental design, statistical interpretation, and downstream hypothesis prioritization.

A strong genome-wide analysis workflow therefore has to do more than test variants one by one. It must manage three separate threats at the same time. The first is multiplicity. When millions of hypotheses are tested together, nominal significance becomes cheap. The second is confounding by ancestry structure and cryptic relatedness. Even small biases can become powerful in large cohorts. The third is linkage disequilibrium. An association peak often marks a correlated block, not a single functional allele.

Those three threats also define the three technical layers that matter most:

• error-rate control,
• structure correction,
• and causal prioritization.

If one layer is weak, the rest of the workflow becomes harder to trust. That is why the most useful modern GWAS discussions begin with statistical rigor, not with biology-first storytelling. Biology matters, but only after the association framework has earned confidence.

For projects that begin with new sample generation rather than public data reuse, upstream assay quality still shapes everything that follows. Stable genotype data, consistent coverage, and defensible variant calling reduce downstream uncertainty before association modeling even begins. Depending on study scope, that may mean starting from whole genome sequencing, pairing cohort-scale analysis with structured variant calling, or using large-panel whole genome SNP genotyping when common-variant coverage is the main priority.

Statistical rigor starts where visual significance becomes misleading

A Manhattan plot is persuasive because it compresses complexity into height. Taller peaks look stronger. Dense clusters look more convincing. But the image hides a crucial fact: not every strong-looking signal represents the same kind of evidence.

Some peaks are inflated by multiple testing alone. Some reflect ancestry-correlated variation rather than phenotype biology. Some are real association signals but still fail to identify the true functional variant. If those cases are treated as equivalent, the workflow becomes visually clear but scientifically weak.

This is why statistical rigor in genome-wide analysis should be described as a sequence of filters rather than a single threshold. One filter controls how much false signal the project is willing to tolerate. Another models whether the cohort itself is pushing the association pattern in misleading directions. A third filter asks whether the top-ranked variant is actually the best candidate for downstream validation.

When these filters are applied in a disciplined order, the output becomes more interpretable. The result may contain fewer dramatic claims, but the surviving claims are much more useful. That tradeoff is often the correct one in research settings, especially when significant loci will later guide fine-mapping, functional assays, or cohort stratification.

Figure 1. Statistical distortion in genome-wide analysis arises from different sources, and each correction layer removes a different class of false confidence before biological interpretation begins.

The multiple testing paradox in very large datasets

The standard multiple testing problem is straightforward in principle. If a study tests one million variants, even a very low nominal false-positive rate will still produce misleading hits by chance. A p-value that looks convincing in a small study may be trivial in a genome-wide scan.

That is why strict thresholding became central to GWAS practice. Bonferroni correction is the clearest version of that logic. It divides the target alpha by the number of tests and protects against family-wise error. In plain terms, it asks how strict the study must be if even one false positive across the full testing space is unacceptable.

The appeal of Bonferroni is obvious. It is transparent. It is simple to explain. It produces a short list of loci that look hard to dismiss. If downstream validation is expensive or the project is designed around a very conservative discovery set, Bonferroni-style control remains a defensible choice.

Its weakness is also obvious once the search space becomes massive. The stricter the correction, the more real but moderate signals disappear with the noise. This creates the central multiple testing paradox in genome-wide analysis: broader search increases the chance of detecting real biology, but the threshold needed to control false positives can become so severe that it suppresses weaker true effects at the same time.

False discovery rate control approaches the same problem from a different angle. Instead of asking how to avoid any false positive at all, FDR asks what proportion of called discoveries can be tolerated as false. That shift changes the purpose of the threshold.

Bonferroni is best suited to confirmation-oriented discovery. FDR is often better suited to candidate-preserving discovery.

That does not make FDR sloppy. It makes it goal-aware. In many real GWAS workflows, the objective is not to produce one final immutable list of loci. The objective is to preserve a meaningful candidate space that can then be narrowed by replication, fine-mapping, colocalization, and functional integration. In that context, FDR can be the more practical first-pass framework.

The mistake is to treat these methods as moral opposites. They are not. They answer different questions:

• Bonferroni asks how to protect against any false positive in the tested family.
• FDR asks how to manage the expected proportion of false discoveries among retained hits.
• Bonferroni favors short, hard-to-argue-with lists.
• FDR favors broader discovery layers that remain open to downstream pruning.

In advanced projects, the best solution is often to use both ideas at different stages. One threshold defines the strict core association layer. Another preserves a wider candidate set for fine-mapping and mechanism-oriented follow-up. This is especially useful when the study design is not built around peak reporting alone, but around causal prioritization.

The practical lesson is simple: significance is not a single universal state. It depends on how the project defines error, what it plans to do with retained loci, and how much uncertainty it is prepared to carry into the next stage.

Population stratification is not a minor covariate issue

Population stratification is often introduced as a nuisance factor. That wording is too soft. In large genome-wide studies, it is a structural threat.

The problem appears when allele frequencies differ across subgroups and those subgroups also differ in phenotype prevalence for reasons unrelated to the causal variant under study. If that structure is not handled properly, the model can confuse cohort composition with biology. The resulting signal may look stable, statistically strong, and biologically plausible while still being driven by confounding.

This is one reason some association peaks collapse when cohort design changes, when ancestry composition shifts, or when more rigorous structure correction is applied. The issue is not that the analysis lacked power. The issue is that the model assigned too much meaning to structured variation.

Principal components analysis remains one of the most useful tools for diagnosing and adjusting ancestry structure. PCA compresses major axes of variation into continuous components that can be added as fixed covariates. It is computationally efficient, interpretable, and still highly valuable for exploratory cohort assessment. In many datasets, it handles broad structure well enough to improve calibration substantially.

But PCA has clear limits.

PCA captures dominant variation axes. It does not fully model all sample covariance. It does not fully absorb cryptic relatedness. It does not fully represent distributed kinship-like structure that can remain after broad ancestry trends are removed. In moderate and large cohorts, especially those with subtle family structure or heterogeneous sampling history, residual confounding can survive PCA-only correction.

That is where linear mixed models become important.

Why linear mixed models changed modern GWAS practice

A linear mixed model adds a random-effect component that captures covariance among individuals, often through a genetic relationship matrix or a closely related representation. This changes the logic of correction.

PCA says: regress out major structure axes.
LMM says: model correlated background directly.

That difference is not cosmetic. It is the reason mixed-model association became central in large, structured cohorts. Instead of relying only on a handful of fixed covariates, the model recognizes that individuals may share background genetic similarity in ways that influence association statistics across the genome.

This makes LMM particularly valuable when:

• cryptic relatedness is likely,
• subtle kinship remains after basic QC,
• cohort size is large enough that weak confounding becomes highly significant,
• sample structure is diffuse rather than cleanly separated,
• or downstream interpretation depends on marginal signals that would be vulnerable to inflation.

In these settings, mixed-model association is not a luxury feature. It is part of the core inferential design.

That does not mean PCA becomes irrelevant. Good workflows often use both. PCA remains useful for ancestry visualization, outlier detection, exploratory sample assessment, and fixed-effect covariate modeling. LMM then adds a stronger second layer of protection during association testing itself. One helps describe the cohort. The other helps stabilize the inference drawn from it.

This is also where software choice becomes meaningful. A standard regression-based workflow may be fully adequate in one cohort and inadequate in another. The decision should follow sample architecture, not analyst habit. For locus-focused follow-up after broad discovery, some projects also move into narrower assay designs such as targeted region sequencing or a custom SNP fine mapping workflow once the broader association space has already been reduced.

How to tell when PCA-only correction is not enough

Many studies include principal components because that step is standard. Fewer studies explain why the chosen correction strategy was sufficient for that cohort. That is where stronger technical writing can add value.

PCA-only correction may be adequate when the cohort is relatively clean, relatedness is limited, structure is broad rather than deeply nested, and the project is not leaning heavily on borderline signals. It becomes less reassuring when the dataset is large, recruitment is heterogeneous, or hidden covariance patterns are plausible.

The question is not whether PCs were included. The question is whether the structure problem was actually solved.

Several warning signs should trigger caution:

• residual inflation after standard correction,
• association shifts that track ancestry composition,
• unexpected persistence of weak genome-wide signal,
• strong effects in regions known to be sensitive to structure,
• or unstable results across related but differently filtered cohort subsets.

These signals do not automatically prove that PCA failed. They do indicate that the project may need a stronger covariance model.

The broader lesson is worth stating clearly: population correction should be designed, not inherited. Too many GWAS pipelines still reuse the last project's structure-adjustment recipe with minimal justification. That is risky in 2026-scale data, where subtle confounding can be statistically amplified long before it becomes visually obvious.

The LD bottleneck begins where many GWAS summaries end

Once association testing is complete, many readers jump to the most significant SNP and ask which variant caused the phenotype shift. That question is understandable. It is also usually premature.

The lead SNP is the variant with the strongest association statistic in the tested data. It is not automatically the variant that changes expression, alters splicing, perturbs chromatin, or directly drives phenotype biology. In many loci, the lead SNP is simply the best statistical tag for a nearby causal allele because multiple variants are correlated through linkage disequilibrium.

This is the LD bottleneck.

Association detects a region. Biology needs a variant. The gap between those two levels is exactly where many superficial GWAS interpretations overreach.

In a locus with strong LD, several neighboring variants may rise together. Their p-values can be similar. Their rank order can shift across ancestry groups, imputation panels, or cohort designs. That instability is not a technical nuisance. It is a clue. It tells the analyst that the signal represents a correlated neighborhood rather than a single resolved mechanism.

A mature workflow therefore treats the lead SNP as an entry point, not a final answer. This is especially important when the study is expected to support downstream perturbation work, expression follow-up, or regulatory validation. Experimental teams do not need the loudest SNP. They need the most defensible candidate set.

That need often pushes the project beyond pure association data and into function-oriented assays. When the goal is to connect locus-level statistics to regulatory mechanism, teams may combine association findings with RNA-Seq, targeted chromatin profiling such as ATAC-Seq, or broader coordinated multi-omics service support to determine whether prioritized variants sit in a plausible regulatory context.

Figure 2. An association peak usually represents an LD-defined neighborhood rather than a single mechanistic answer, which is why lead-SNP ranking must be followed by credible-set prioritization.

Fine-mapping is the real bridge between association and causality

Fine-mapping exists because GWAS and mechanism operate at different resolutions. GWAS is optimized to detect loci associated with a phenotype. Fine-mapping is optimized to decide which variants inside that locus still deserve belief after LD structure is accounted for.

That distinction is fundamental.

A useful way to frame the relationship is this:

• GWAS asks which locus matters.
• Fine-mapping asks which variants inside that locus remain plausible causal candidates.

Once stated that way, the need for fine-mapping becomes obvious. Association ranking alone cannot answer a causal question when many correlated variants move together.

Frequentist refinement often approaches this problem through conditional testing and iterative significance evaluation. That can help determine whether the locus contains multiple independent signals. It remains useful. But it still tends to speak the language of threshold survival.

Bayesian fine-mapping changes the conversation by asking how support should be distributed across candidate variants and candidate causal configurations. Instead of asking only whether a variant remains significant after conditioning, it asks how much posterior belief each candidate should receive given the observed pattern and the local LD structure.

That shift is powerful because experiments are expensive. Most teams cannot test every variant in an associated block. They need a ranked, uncertainty-aware shortlist. Bayesian fine-mapping provides exactly that.

A posterior inclusion probability is not a guarantee of truth. A credible set is not a promise that the causal variant has been captured with certainty. But both are far more honest and operationally useful than pretending that the top association signal has already solved the mechanism.

This also improves the handoff between computational and experimental teams. A weak workflow sends one SNP downstream with too much confidence. A stronger workflow sends a ranked candidate set, explains why uncertainty remains, and clarifies what kind of functional evidence would shrink that uncertainty further.

That is where the second half of the article begins. Once a locus has been fine-mapped into a credible candidate space, the next question is no longer which region is associated. The next question is how those candidate variants connect to expression, splicing, regulatory state, and eventually to cohort-level architectures such as polygenic risk scores.

Multi-omic integration turns associated loci into biological hypotheses

Fine-mapping narrows the candidate space. It does not complete the biological story.

A credible set is still a statistical object. It tells us which variants remain plausible after LD-aware modeling. It does not yet tell us how those variants act, which tissue context matters most, whether the main effect is on expression or splicing, or which gene in the region is the true effector gene. That is the point where multi-omic integration becomes necessary.

The weakest version of this step is simple overlap. A study identifies a GWAS locus, finds that the same region contains an eQTL, and then assigns the nearby gene as the likely mechanism. That approach is common because it is fast and easy to explain. It is also often incomplete. Many loci do not resolve cleanly through expression data alone, and some are better explained by splicing, chromatin accessibility, or regulatory context that is not visible in bulk eQTL summaries. Recent work continues to support the idea that multi-layer QTL interpretation can expose mechanisms that would be missed by an eQTL-only reading.

That is why serious post-GWAS interpretation should be framed as causal triangulation, not annotation.

A robust triangulation workflow asks a linked set of questions:

• Does the credible set colocalize with an eQTL signal?
• Does the same region alter transcript structure through an sQTL effect?
• Is the candidate variant located in open chromatin or another active regulatory element?
• Does the implicated gene make biological sense in the tissue or cell type relevant to the phenotype?
• Do several independent data layers point to the same mechanism, or do they conflict?

The stronger the convergence, the stronger the hypothesis.

eQTL is useful, but it is not the full answer

Expression QTLs remain one of the most valuable bridges between genotype and function. They can explain why a noncoding signal matters, help prioritize effector genes, and move the discussion away from nearest-gene assumptions. But they have limits that need to be stated plainly.

First, eQTL effects are context-dependent. A variant may regulate expression in one tissue and not another. It may act only in a developmental window, under a stimulation state, or in a rare cell type that bulk tissue data cannot resolve. Second, total expression is only one outcome. Some variants change isoform balance, exon inclusion, or transcript usage without producing a large total-expression shift. Third, shared regional signal does not prove shared causality. A GWAS peak and an eQTL peak can overlap in the same LD block while still being driven by different underlying variants.

This is where sQTL evidence becomes especially valuable. A locus that looks modest in eQTL space may become much more compelling once splice-aware data is considered. For that reason, post-GWAS interpretation often becomes much stronger when standard transcriptome profiling is paired with isoform-resolving or transcript-structure-aware workflows.

In practical research settings, that can mean combining RNA-Seq with Full-Length Transcripts Sequencing (Iso-Seq) when isoform architecture matters, or adding ATAC-Seq when regulatory accessibility is part of the hypothesis. When the mechanism is likely distributed across several molecular layers, a coordinated multi-omics service framework can be more informative than a single-assay follow-up. These service directions come from the file you provided.

Colocalization is more rigorous than overlap

One of the most common mistakes in GWAS interpretation is to treat genomic proximity as mechanistic evidence. The locus overlaps an eQTL, therefore the gene is causal. That step is too fast.

Colocalization imposes a much stricter question: are the GWAS signal and the molecular QTL signal consistent with the same underlying causal variant, or are they simply neighboring signals inside the same LD block? That distinction matters because overlap without colocalization can create false narrative certainty.

A strong interpretation chain therefore looks like this:

1. detect the associated locus,
2. fine-map the credible candidate set,
3. test colocalization with eQTL or sQTL data,
4. evaluate tissue and cell-type relevance,
5. integrate chromatin or regulatory evidence,
6. prioritize the most defensible effector gene or regulatory mechanism.

This is slower than assigning the nearest gene. It is also much more credible.

Multi-omic integration should reduce uncertainty, not decorate the result

There is a subtle but important principle here. More data does not automatically mean more inference. Multi-omic integration is valuable only when it reduces uncertainty.

If eQTL, sQTL, open chromatin, and pathway context all converge on the same gene or regulatory event, confidence rises. If those layers disagree, the result is not failure. It is a useful constraint. The project has learned that the mechanism is still unresolved and that targeted validation should be designed accordingly.

That is the right mindset for advanced genome-wide analysis. The goal is not to produce the most crowded figure. The goal is to move from association to mechanism with the fewest unjustified leaps.

Figure 3. Multi-omic interpretation is strongest when several functional layers converge on the same candidate mechanism, while PRS uses those statistically grounded loci to model cohort-level signal rather than single-locus causality.

Polygenic risk scores are an aggregation problem built on upstream rigor

Once the analysis moves beyond individual loci, the next temptation is to compress the architecture into a single score. Polygenic risk scores do exactly that. They aggregate weighted effects across many loci to model distributed inherited signal at the cohort level.

This is useful. It is also easy to misuse.

A PRS inherits the strengths and weaknesses of every step before it. If the association layer is biased, the score inherits that bias. If ancestry structure is poorly handled, transferability suffers. If LD is modeled carelessly, the score can be unstable. If effect sizes are estimated in a population that does not match the target cohort, performance can degrade sharply. Recent reviews and method papers continue to emphasize that PRS accuracy remains strongly shaped by ancestry, LD handling, model priors, and the way effect-size shrinkage is implemented.

What PRS does well in research cohorts

PRS is most useful when it is treated as a model of distributed signal rather than a shortcut to mechanistic explanation.

In research workflows, PRS can help:

• stratify samples into burden-defined groups,
• test whether signal is diffuse or concentrated,
• enrich cohorts for downstream comparisons,
• compare architecture across related traits,
• and provide a cohort-level complement to locus-level biology.

That framing is important. PRS answers a different question from fine-mapping. Fine-mapping asks which variants inside a locus remain plausible causal candidates. PRS asks how many weighted loci, taken together, explain variance across the cohort.

These are not competing goals. They operate at different levels of resolution.

The real challenge is not summation. It is weighting.

At a glance, PRS looks simple. Count alleles. Weight them by effect size. Sum across loci. But nearly every part of that sentence hides a modeling choice.

• Which loci are included?
• Are only genome-wide significant loci used?
• Are sub-threshold variants retained?
• How is LD handled?
• Are effect sizes shrunk?
• Are functional annotations used to inform weighting?
• Is the score calibrated in an ancestry-matched population?

Each of these decisions changes the final score.

A score built only from top signals is easier to explain, but it can miss diffuse architecture. A broader score may capture more variance, but it can also import more noise if LD pruning, shrinkage, or ancestry matching are weak. Annotation-informed models attempt to solve part of this problem by using biological priors to upweight variants that are more likely to be functionally meaningful. That direction is becoming more attractive as researchers try to combine predictive modeling with mechanistic plausibility.

PRS should follow good association design, not replace it

One of the easiest ways to weaken a GWAS article is to let PRS appear as an upgrade path that bypasses locus-level rigor. It is not.

PRS is strongest when it sits on top of good association design, good structure correction, and good locus interpretation. In a mature workflow:

• association establishes which regions matter,
• fine-mapping narrows candidate variants,
• multi-omic data clarifies plausible function,
• PRS aggregates distributed effects across the cohort.

That is the correct order of ideas.

For teams planning cohort-scale score construction, platform choice also matters. Depending on architecture, budget, and desired locus density, the upstream data source may come from whole exome sequencing, human/mouse whole exome sequencing, SNP microarray, or genotyping by sequencing (GBS). Those options come from the service inventory you provided and fit different research-scale PRS designs.

Machine learning for epistasis is valuable, but mostly as a screening layer

Machine learning enters genome-wide analysis for a simple reason. Classical GWAS is strongest for additive effects tested one marker at a time. Biology is not always additive. Gene-gene interactions, threshold behavior, and nonlinear combinations may matter. Random Forests and related methods are therefore attractive because they can search for interaction patterns that ordinary marginal association can miss.

That promise is real. The common overclaim is that machine learning therefore replaces classical GWAS. It does not.

Recent work on polygenic prediction continues to show that more complex models do not automatically outperform strong linear or mixed-model baselines. In many settings, the expected gain from nonlinearity is smaller than claimed, and some reported improvements shrink when benchmarking becomes more rigorous.

This does not make machine learning irrelevant. It defines its proper role.

Where Random Forests and related models add real value

Machine-learning models are useful when the research question is exploratory:

• are there candidate non-linear interactions worth testing?
• do certain variant combinations split the cohort in unexpected ways?
• are there high-order feature patterns that deserve targeted follow-up?

In that setting, machine learning acts as a screening tool. It proposes candidates for deeper analysis. It does not replace the statistical framework that established the underlying locus credibility in the first place.

That role is especially sensible for epistasis work. The full interaction space is enormous. A well-designed ML stage can help narrow the search to patterns worth formal evaluation, but only if the workflow already has disciplined preprocessing, ancestry control, and a strong baseline model for comparison.

The three main pitfalls in ML-based epistasis analysis

The first pitfall is feature explosion. The number of possible interactions grows rapidly, and most of them are uninformative. Without prior filtering, the model spends too much effort on noise.

The second pitfall is interpretability loss. A predictive structure may be real without being mechanistically informative. A model can also learn ancestry-correlated or LD-redundant patterns that look biologically interesting but are not.

The third pitfall is weak benchmarking. A complex model only looks impressive if the baseline is underbuilt. The correct comparison is not against a simplistic additive model built casually. It is against a strong, LD-aware, ancestry-aware baseline built well.

That is why machine learning should usually come late in the workflow. It adds the most value after the study has already established stable association structure and credible candidate loci.

Software choice should follow cohort structure, not habit

Many summaries mention PLINK, BOLT-LMM, and REGENIE in the same breath, as though they are interchangeable. They are not. They overlap in purpose, but they solve different problems with different strengths. Official documentation makes that clear: PLINK 2.0 emphasizes fast standard association workflows, BOLT-LMM focuses on mixed-model association in large cohorts, and REGENIE is designed for scalable whole-genome regression at modern cohort scale.

GWAS software comparison

This is not a winner-take-all table. It is a matching table.

How to choose in practice

Choose PLINK when the main priority is speed, transparent baseline association, strong QC integration, and a cohort where subtle kinship is not the main inferential threat.

Choose BOLT-LMM when the project depends on mixed-model correction in a large human cohort with distributed relatedness and polygenic background.

Choose REGENIE when scale, throughput, and efficient large-cohort association matter most, especially when the project must run many traits or large binary-trait analyses.

The best software choice is always tied to cohort architecture. It is never just a matter of popularity.

What advanced genome-wide analysis should look like now

A mature genome-wide analysis workflow should not stop at significance, and it should not collapse association, mechanism, and prediction into one claim.

A stronger operating model looks like this:

1. generate or curate stable variant data,
2. choose an error-control strategy that matches the project goal,
3. model ancestry and relatedness rigorously,
4. treat lead SNPs as starting points rather than conclusions,
5. fine-map loci under LD-aware uncertainty,
6. test mechanistic hypotheses through eQTL, sQTL, and regulatory integration,
7. use PRS to summarize distributed architecture at the cohort level,
8. apply machine learning selectively for interaction screening,
9. choose software according to scale and structure,
10. communicate uncertainty clearly at each handoff.

That sequence matters because each stage answers a different question. Association asks where the signal is. Fine-mapping asks which variants remain plausible. Multi-omic integration asks how the signal may act. PRS asks how signal accumulates across the cohort. Machine learning asks whether higher-order patterns deserve further scrutiny.

The field has not moved beyond the Manhattan plot by abandoning it. It has moved beyond it by refusing to let one image carry more meaning than it should.

FAQ

What is the main limitation of a Manhattan plot?

A Manhattan plot shows association strength, but it does not by itself distinguish true biology from false discovery, unresolved LD, or cohort-structure artifacts.

When is FDR more useful than Bonferroni in GWAS?

FDR is often more useful in discovery-oriented workflows where the goal is to preserve a broader candidate set for downstream fine-mapping and functional prioritization.

Why are linear mixed models often better than PCA alone?

PCA captures major ancestry axes, while LMMs model broader covariance and relatedness. In large or subtly structured cohorts, that often produces cleaner association results.

When should fine-mapping follow standard GWAS?

Fine-mapping should follow GWAS whenever the project needs causal prioritization rather than peak reporting alone, especially before functional validation or mechanistic follow-up.

Why integrate GWAS with both eQTL and sQTL data?

Because some loci act mainly through expression, while others act through transcript structure or isoform usage. Using both layers gives a more complete view of regulatory function.

Does PRS replace locus-level interpretation?

No. PRS summarizes distributed cohort-level signal. It complements fine-mapping and multi-omic interpretation rather than replacing them.

How should machine learning be used in GWAS research?

Best as a screening layer for nonlinear interaction discovery, after the study has already established strong baseline association and structure correction.

How do you choose between PLINK, BOLT-LMM, and REGENIE?

Choose based on cohort architecture and workflow scale: PLINK for fast baseline regression, BOLT-LMM for large mixed-model human cohorts, and REGENIE for efficient large-scale high-throughput association.

References

1. Korte A, Farlow A. The advantages and limitations of trait analysis with GWAS: a review. Plant Methods. 2013;9:29. DOI: 10.1186/1746-4811-9-29
2. Marees AT, de Kluiver H, Stringer S, et al. A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. International Journal of Methods in Psychiatric Research. 2018;27(2):e1608. DOI: 10.1002/mpr.1608
3. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics. 2006;38(8):904-909. DOI: 10.1038/ng1847
4. Kang HM, Sul JH, Service SK, et al. Variance component model to account for sample structure in genome-wide association studies. Nature Genetics. 2010;42(4):348-354. DOI: 10.1038/ng.548
5. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics. 2016;32(10):1493-1501. DOI: 10.1093/bioinformatics/btw018
6. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection in regression, with application to genetic fine mapping. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2020;82(5):1273-1300. DOI: 10.1111/rssb.12388
7. Zhang X, Jiang W, Zhao H. Integration of expression QTLs with fine mapping via SuSiE. PLoS Genetics. 2024;20(1):e1010929. DOI: 10.1371/journal.pgen.1010929
8. Vosa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nature Genetics. 2021;53(9):1300-1310. DOI: 10.1038/s41588-021-00913-z
9. Li YI, Knowles DA, Humphrey J, et al. Annotation-free quantification of RNA splicing using LeafCutter. Nature Genetics. 2018;50(1):151-158. DOI: 10.1038/s41588-017-0004-9
10. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nature Communications. 2019;10:1776. DOI: 10.1038/s41467-019-09718-5
11. Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nature Protocols. 2020;15:2759-2772. DOI: 10.1038/s41596-020-0353-1
12. PLINK 2.0 association analysis documentation. Link: PLINK 2.0 association analysis
13. BOLT-LMM user manual. Link: BOLT-LMM manual
14. REGENIE documentation. Link: REGENIE documentation

For research use only. Not for diagnostic procedures.